Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin.
OBJECTIVE
To report a newly recognized adverse effect of oral moxifloxacin.


METHODS
Observational case reports.


METHODS
Five patients who used oral moxifloxacin therapy.


METHODS
In five patients, a uveitis-like episode followed oral moxifloxacin therapy, afterwards they experienced photophobia. At slitlamp investigation, the patients showed almost complete iris transillumination, not restricted to one sector, and persistent mydriasis of the pupil, with no reaction to light and no near reflex. Follow-up of 3 years in one of the patients showed no change of symptoms. Only in one patient, with a history of anterior uveitis, an anterior chamber tap was positive for herpes simplex genome. Only after the use of moxifloxacin did she experience continuous photophobia.


CONCLUSIONS
Iris transillumination and sphincter paralysis is a newly recognized adverse effect of oral moxifloxacin therapy.
Wefers Bettink-Remeijer
M
M
Het Oogziekenhuis Rotterdam, Rotterdam Eye Hospital, Schiedamse Vest 180, Rotterdam, The Netherlands. m.wefers@oogziekenhuis.nl
Brouwers
K
K
van Langenhove
L
L
De Waard
P W T
PW
Missotten
T O
TO
Martinez Ciriano
J P
JP
Van Aken
E
E
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001372:Aza Compounds / Q000009:adverse effects*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007499:Iris Diseases / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D000077266:Moxifloxacin; D020795:Photophobia / Q000209:etiology; D011804:Quinolines / Q000009:adverse effects*; D014172:Transillumination; D014605:Uveitis / Q000139:chemically induced* / Q000473:pathology
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin